<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40998847</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>25</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>25</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Meta-analysis of comprehensive prognostic evaluation in patients with atrial fibrillation complicated by heart failure after catheter ablation.</ArticleTitle><Pagination><StartPage>32785</StartPage><MedlinePgn>32785</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-16166-3</ELocationID><Abstract><AbstractText>Atrial fibrillation (AF) and heart failure (HF) often coexist, posing increased risks of HF events, rehospitalization, mortality, and stroke. While antiarrhythmic drugs have limitations, catheter ablation (CA) has emerged as a preferred rhythm control treatment for AF, yet its clinical outcomes remain inconclusive. Previous meta-analyses have predominantly included randomized controlled trials (RCTs) or cohort studies with limited sample sizes and outcome measures, which do not comprehensively and accurately reflect the clinical prognosis of patients with AF and HF following CA. However, the high prevalence of AF and HF comorbidity and the significant economic burden it imposes underscore the importance of focusing on the clinical prognosis of these patients. This meta-analysis systematically includes high-quality RCTs and cohort studies in evidence-based medicine, comprising a total of 34 studies and 777,668 patients.Meta-analysis revealed that CA significantly reduced the risk of HF events (RR, 0.63; 95% CI, 0.51-0.77), cardiovascular (CV) mortality (RR, 0.54; 95% CI, 0.45-0.66), CV hospitalization (RR, 0.81; 95% CI, 0.71-0.93), all-cause mortality (RR, 0.57; 95% CI, 0.46-0.70), all-cause rehospitalization (RR, 0.87; 95% CI, 0.76-0.996),AF recurrence (RR, 0.45; 95% CI, 0.36-0.57), and stroke (RR, 0.69; 95% CI, 0.57-0.83) when compared to NCA. CA demonstrated superior benefits in improving outcomes for patients with AF and HF, including HF events, mortality, rehospitalization, AF recurrence and incidence of stroke. Additionally, CA shows similar therapeutic effects in improving cardiac structure, cardiopulmonary function, and quality of life.These findings support the efficacy of CA in managing AF and HF.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Xiaoting</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Cardiac Pacing and Electrical Engineering, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiac Electrophysiology and Cardiac Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wei</LastName><ForeName>Meng</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Cardiac Pacing and Electrical Engineering, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiac Electrophysiology and Cardiac Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Pengjie</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiac Pacing and Electrical Engineering, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiac Electrophysiology and Cardiac Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Baopeng</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Cardiac Pacing and Electrical Engineering, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China. tangbaopeng1111@163.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Xinjiang Key Laboratory of Cardiac Electrophysiology and Cardiac Remodeling, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, 830000, Xinjiang, China. tangbaopeng1111@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022B03023</GrantID><Agency>Key R&amp;D Program of Xinjiang Uygur Autonomous Region</Agency><Country/></Grant><Grant><GrantID>2022B03023</GrantID><Agency>Key R&amp;D Program of Xinjiang Uygur Autonomous Region</Agency><Country/></Grant><Grant><GrantID>2022B03023</GrantID><Agency>Key R&amp;D Program of Xinjiang Uygur Autonomous Region</Agency><Country/></Grant><Grant><GrantID>2022B03023</GrantID><Agency>Key R&amp;D Program of Xinjiang Uygur Autonomous Region</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001281" MajorTopicYN="Y">Atrial Fibrillation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017115" MajorTopicYN="Y">Catheter Ablation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atrial fibrillation</Keyword><Keyword MajorTopicYN="N">Cardiovascular</Keyword><Keyword MajorTopicYN="N">Catheter ablation</Keyword><Keyword MajorTopicYN="N">Heart failure</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>26</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>25</Day><Hour>23</Hour><Minute>20</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40998847</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-16166-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-16166-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pabel, S. &amp; Sossalla, S. Atrial fibrillation and heart failure: novel insights into the chicken and egg dilemma. Eur. Heart J. 43, 3376&#x2013;3378 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35653688</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehac257</ArticleId></ArticleIdList></Reference><Reference><Citation>Odutayo, A. et al. Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis. BMJ (Clin Res. ed,) 354, i4482 (2016).</Citation></Reference><Reference><Citation>Joglar, J. A. et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. Circulation 149, e1&#x2013;e156 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38033089</ArticleId><ArticleId IdType="doi">10.1161/CIR.0000000000001193</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Biase, L. et al. Ablation versus Amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device: results from the AATAC multicenter randomized trial. Circulation 133, 1637&#x2013;1644 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27029350</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.115.019406</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher, N., Metzner, A., Toennis, T., Kirchhof, P. &amp; Schnabel, R. B. Atrial fibrillation burden: a new outcome predictor and therapeutic target. Eur. Heart J. 45, 2824&#x2013;2838 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38953776</ArticleId><ArticleId IdType="pmc">11328870</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehae373</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder, B. A., Rienstra, M., Van Gelder, I. C. &amp; Blaauw, Y. Update on management of atrial fibrillation in heart failure: a focus on ablation. Heart 108, 422&#x2013;428 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34088767</ArticleId><ArticleId IdType="doi">10.1136/heartjnl-2020-318081</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, D. G. et al. A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure. J. Am. Coll. Cardiol. 61, 1894&#x2013;1903 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">23500267</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2013.01.069</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazi, D. S. et al. Forecasting the economic burden of cardiovascular disease and stroke in the united States through 2050: a presidential advisory from the American heart association. Circulation 150, e89&#x2013;e101 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38832515</ArticleId><ArticleId IdType="doi">10.1161/CIR.0000000000001258</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashemi, D. et al. Economic impact of heart failure with preserved ejection fraction: insights from the ALDO-DHF trial. ESC Heart Fail. 7, 786&#x2013;793 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31984661</ArticleId><ArticleId IdType="pmc">7261555</ArticleId><ArticleId IdType="doi">10.1002/ehf2.12606</ArticleId></ArticleIdList></Reference><Reference><Citation>Newman, J. D. et al. Implications of atrial fibrillation for guideline-directed therapy in patients with heart failure: JACC state-of-the-art review. J. Am. Coll. Cardiol. 83, 932&#x2013;950 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38418008</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2023.12.033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsao, C. W. et al. Heart disease and stroke statistics-2022 update: a report from the American heart association. Circulation 145, e153&#x2013;e639 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35078371</ArticleId><ArticleId IdType="doi">10.1161/CIR.0000000000001052</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh, T. A. et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 42, 3599&#x2013;3726 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34447992</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehab368</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbelo, E. et al. [2023 ESC Guidelines for the management of cardiomyopathies]. G. Ital. Cardiol. () 24, e1&#x2013;e127 (2023).) 24, e1&#x2013;e127 (2023). (2006).</Citation></Reference><Reference><Citation>Pabel, S. et al. Effects of atrial fibrillation on the human ventricle. Circ. Res. 130, 994&#x2013;1010 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35193397</ArticleId><ArticleId IdType="pmc">8963444</ArticleId><ArticleId IdType="doi">10.1161/CIRCRESAHA.121.319718</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulus, M. G. et al. Tachycardiomyopathy entails a dysfunctional pattern of interrelated mitochondrial functions. Basic. Res. Cardiol. 117, 45 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36068416</ArticleId><ArticleId IdType="pmc">9448689</ArticleId><ArticleId IdType="doi">10.1007/s00395-022-00949-0</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi, A. D., Hematpour, K., Kukin, M., Mittal, S. &amp; Steinberg, J. S. Ablation vs medical therapy in the setting of symptomatic atrial fibrillation and left ventricular dysfunction. Congestive Heart Fail. 16, 10&#x2013;14 (2010).</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-7133.2009.00116.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, B. O. et al. Optimal treatment of underlying conditions improves rhythm control outcome in atrial fibrillation - data from RACE 3. Am. Heart J. 226, 235&#x2013;239 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32067695</ArticleId><ArticleId IdType="doi">10.1016/j.ahj.2019.12.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Hindricks, G. et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for cardio-thoracic surgery (EACTS): the task force for the diagnosis and management of atrial fibrillation of the European society of cardiology (ESC) developed with the special contribution of the European heart rhythm association (EHRA) of the ESC. Eur. Heart J. 42, 373&#x2013;498 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32860505</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehaa612</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrade, J. G. et al. Healthcare utilization and quality of life for atrial fibrillation burden: the CIRCA-DOSE study. Eur. Heart J. 44, 765&#x2013;776 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36459112</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehac692</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, F. C. Observation of the therapeutic efficacy of radiofrequency ablation for persistent atrial fibrillation combined with heart failure in rhythm control. Pract. Clin. Pract. Integr. Med. 22, 16&#x2013;18 (2022).</Citation></Reference><Reference><Citation>Bunch, T. J. et al. Five-year outcomes of catheter ablation in patients with atrial fibrillation and left ventricular systolic dysfunction. J. Cardiovasc. Electrophysiol. 26, 363&#x2013;370 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25534572</ArticleId><ArticleId IdType="doi">10.1111/jce.12602</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuck, K. H. et al. Catheter ablation versus best medical therapy in patients with persistent atrial fibrillation and congestive heart failure: the randomized AMICA trial. Circ. Arrhythm. Electrophysiol. 12, e007731 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">31760819</ArticleId><ArticleId IdType="doi">10.1161/CIRCEP.119.007731</ArticleId></ArticleIdList></Reference><Reference><Citation>R, P. et al. Randomized ablation-based rhythm-control versus rate-control trial in patients with heart failure and atrial fibrillation: results from the RAFT-AF trial. Circulation 145, 1693&#x2013;1704 (2022).</Citation></Reference><Reference><Citation>Sohns, C. et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N. Engl. J. Med. 389, 1380&#x2013;1389 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37634135</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa2306037</ArticleId></ArticleIdList></Reference><Reference><Citation>Marrouche, N. F. et al. Catheter ablation for atrial fibrillation with heart failure. N Engl. J. Med. 378, 417&#x2013;427 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29385358</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1707855</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter, R. J. et al. A randomized controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the CAMTAF trial). Circ. Arrhythm. Electrophysiol. 7, 31&#x2013;38 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24382410</ArticleId><ArticleId IdType="doi">10.1161/CIRCEP.113.000806</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukui, A. et al. Catheter ablation of atrial fibrillation reduces heart failure rehospitalization in patients with heart failure with preserved ejection fraction. J. Cardiovasc. Electrophysiol. 31, 682&#x2013;688 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">31985099</ArticleId><ArticleId IdType="doi">10.1111/jce.14369</ArticleId></ArticleIdList></Reference><Reference><Citation>Chieng, D. et al. Atrial fibrillation ablation for heart failure with preserved ejection fraction: a randomized controlled trial. JACC: Heart Fail. 11, 646&#x2013;658 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36868916</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald, M. R. et al. Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction: a randomised controlled trial. Heart 97, 740&#x2013;747 (2011).</Citation></Reference><Reference><Citation>Xu, Y., Cai, H. &amp; Li, H. S. Comparison of efficacy of radiofrequency ablation and drug therapy in patients with atrial fibrillation complicated with heart failure. Adv. Cardiovasc. Dis. 43, 274&#x2013;281 (2022).</Citation></Reference><Reference><Citation>Packer, D. L. et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation 143, 1377&#x2013;1390 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33554614</ArticleId><ArticleId IdType="pmc">8030730</ArticleId><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050991</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu, X. Y. &amp; Huang, C. X. The impact of catheter ablation on left ventricular function in atrial fibrillation patients with reduced left ventricular ejection fraction. Chin. J. Cardiovasc. Med. 24, 310&#x2013;313 (2019).</Citation></Reference><Reference><Citation>Sun, J. et al. Comparison of catheter ablation therapy and medication treatment on prognosis in atrial fibrillation patients with heart failure. Liaoning Med. J. 32, 3&#x2013;6 (2018).</Citation></Reference><Reference><Citation>Hunter, R. J. et al. A randomised controlled trial of catheter ablation versus medical treatment of atrial fibrillation in heart failure (the Camtaf trial). PACE - Pacing Clin. Electrophysiol. 34, 1367 (2011).</Citation></Reference><Reference><Citation>Zakeri, R. et al. Long-term outcomes following catheter ablation versus medical therapy in patients with persistent atrial fibrillation and heart failure with reduced ejection fraction. Eur J Heart Fail. 25, 77&#x2013;86 (2023).</Citation></Reference><Reference><Citation>Wong, C. et al. Long-term outcomes following catheter ablation in patients with atrial fibrillation and heart failure: 7-year follow-up of the ARC-HF trial. Circulation 138, 171&#x2013;179 (2018).</Citation></Reference><Reference><Citation>Mohanty, S. et al. Long-term outcome of pulmonary vein isolation versus Amiodarone therapy in patients with coexistent persistent atrial fibrillation and congestive heart failure. Card Fail Rev. 39, 52&#x2013;53 (2018).</Citation></Reference><Reference><Citation>Marrouche, N. F., Kheirkhahan, M. &amp; Brachmann, J. Association between improvement in left ventricular function, mortality and hospitalization post ablation of atrial fibrillation in patients with heart failure -the castle-af trial. Heart Rhythm. 16, 368 (2019).</Citation></Reference><Reference><Citation>Sugumar, H. et al. Catheter ablation versus medication in atrial fibrillation and systolic dysfunction late outcomes of CAMERA-MRI study. JACC: Clin. Electrophysiol. 6, 1721&#x2013;1731 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33334453</ArticleId></ArticleIdList></Reference><Reference><Citation>Prabhu, S. et al. Catheter ablation versus medical rate control in atrial fibrillation and systolic dysfunction: the CAMERA-MRI study. J. Am. Coll. Cardiol. 70, 1949&#x2013;1961 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28855115</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2017.08.041</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Olshausen, G. et al. Catheter ablation for patients with atrial fibrillation and heart failure: insights from the Swedish heart failure registry. Europace 24, i346 (2022).</Citation></Reference><Reference><Citation>Samuel, M., Abrahamowicz, M., Joza, J., Essebag, V. &amp; Pilote, L. Catheter ablation is associated with reduced all-cause mortality in a real-world cohort of patients with atrial fibrillation and heart failure. Canadian J. Cardiology 35, 1006&#x2013;1009 (2019).</Citation></Reference><Reference><Citation>Geng, J. et al. Catheter ablation versus rate control in patients with atrial fibrillation and heart failure: A multicenter study. Med. (Baltim). 96, e9179 (2017).</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000009179</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauber, M. et al. Conduction system pacing with AV node ablation versus catheter ablation for treatment of persistent atrial fibrillation in patients with heart failure with reduced ejection fraction. Europace 24, i261 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac053.178</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman, A. et al. Efficacy of catheter ablation of atrial fibrillation in heart failure with preserved ejection fraction. J. Card. Fail. 25, S84&#x2013;S85 (2019).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cardfail.2019.07.241</ArticleId></ArticleIdList></Reference><Reference><Citation>Lima, F. et al. Hospital readmissions after catheter ablation for atrial fibrillation among patients with heart failure in the united States. Eur. Heart J. 41, 443 (2020).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjci/ehaa946.0443</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel, M. et al. Long-term effectiveness of catheter ablation in patients with atrial fibrillation and heart failure. Europace 22, 739&#x2013;747 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32227165</ArticleId><ArticleId IdType="pmc">7203635</ArticleId><ArticleId IdType="doi">10.1093/europace/euaa036</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel, H. et al. MP-483497-005 impact of catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction. Heart Rhythm. 21, S101&#x2013;S102 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hrthm.2024.03.467</ArticleId></ArticleIdList></Reference><Reference><Citation>Zolotarova, T., Brynza, M. &amp; Bilchenko, O. Outcomes of heart failure with preserved ejection fraction after radiofrequency catheter ablation for atrial fibrillation. Europace 23, iii134 (2021).</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euab116.122</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan, M. N. et al. 34.Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. N Engl J Med. 359, 1778&#x2013;1785 (2008).</Citation></Reference><Reference><Citation>Pasqualotto, E. et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction patients: A meta-analysis. Heart Rhythm. 21, 1604&#x2013;1612 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38705438</ArticleId><ArticleId IdType="doi">10.1016/j.hrthm.2024.04.098</ArticleId></ArticleIdList></Reference><Reference><Citation>Savarese, G. et al. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc. Res. 118, 3272&#x2013;3287 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">35150240</ArticleId><ArticleId IdType="doi">10.1093/cvr/cvac013</ArticleId></ArticleIdList></Reference><Reference><Citation>Becher, P. M., Lund, L. H., Coats, A. J. S. &amp; Savarese, G. An update on global epidemiology in heart failure. Eur. Heart J. 43, 3005&#x2013;3007 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35578978</ArticleId><ArticleId IdType="doi">10.1093/eurheartj/ehac248</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotecha, D. et al. Heart failure with preserved ejection fraction and atrial fibrillation: vicious twins. J. Am. Coll. Cardiol. 68, 2217&#x2013;2228 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27855811</ArticleId><ArticleId IdType="doi">10.1016/j.jacc.2016.08.048</ArticleId></ArticleIdList></Reference><Reference><Citation>Oraii, A. et al. Atrial fibrillation ablation in heart failure with reduced vs preserved ejection fraction: a systematic review and meta-analysis. JAMA Cardiol. https://doi.org/10.1001/jamacardio.2024.0675 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2024.0675</ArticleId><ArticleId IdType="pubmed">38656292</ArticleId><ArticleId IdType="pmc">11044015</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, X., Zhang, X., Fang, X. &amp; Feng, S. Efficacy and safety of catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. Front. Cardiovasc. Med. 11, 1423147. https://doi.org/10.3389/fcvm.2024.1423147 (2024).</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2024.1423147</ArticleId><ArticleId IdType="pubmed">39119189</ArticleId><ArticleId IdType="pmc">11306038</ArticleId></ArticleIdList></Reference><Reference><Citation>Androulakis, E. et al. Catheter ablation for atrial fibrillation in patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis. J. Clin. Med. 11 (2), 288. https://doi.org/10.3390/jcm11020288 (2022).</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm11020288</ArticleId><ArticleId IdType="pubmed">35053984</ArticleId><ArticleId IdType="pmc">8779551</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahalleh, M. et al. Heart failure with preserved ejection fraction and atrial fibrillation: catheter ablation vs. standard medical therapy a systematic review and meta-analysis. Heart Fail. Rev. 30 (1&#x2013;15). https://doi.org/10.1007/s10741-024-10437-3 (2025).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>